Heat Shock Protein 90 in Human Diseases and Disorders

SECTION I: ONCOGENIC ASPECTS OF HSP90.- Chapter 1. Regulatory Roles of HSP90-rich Extracellular Vesicles.- Chapter 2. HSP90-Based Heterocomplex as Essential Regulator for Cancer Disease.- Chapter 3. Therapeutic Potential of Heat Shock Protein 90 Inhibitors in Colorectal Cancer.- Chapter 4. Hsp90 in the Migration of Primordial Germ Cells: A Model to Study Long-Distance Cell Migration and Perhaps Cancer?.- Chapter 5. Role of Heat Shock Protein 90 in Mammary Tumorigenesis.- Chapter 6. Role of HSP90 Inhibitors in the Treatment of Cancer.- Chapter 7. p53-HSP90 Axis in Human Cancer.- Chapter 8. HSP90 and its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve its Clinical Application.- Chapter 9. Hsp90 is a Pivotal Player in Retinal Disease and Cancer.- Chapter 10. Targeting Hsp-90 Related Disease Entities for Therapeutic Development.- Chapter 11. HSP90: A Key Player in Metal-Induced Carcinogenesis?.- Section II: Biomolecular Aspects of HSP90.- Chapter 12. Hsp90 and its Role in Heme-Maturation of Client Proteins: Implications for Human Diseases.- Chapter 13. Moonlighting Functions of Heat Shock Protein 90.- Chapter 14. Hsp90 as a Member of Dicarboxylate Clamp TPR Protein Interaction Network: Implication in Human Diseases and Prospect as a Drug Target.- Chapter 15. 'Complex World' of Hsp90 Co-chaperone R2TP.- Chapter 16. Functions of SGT1, a Co-chaperone.- Chapter 17. Sti1/Hop Plays a Pivotal Role in Hsp90 Regulation beyond Bridging Hsp70.- Section III: HSP90 in Natural Products Development.-Chapter 18. Hsp90: A Target for Susceptibilities and Substitutions in Biotechnological and Medicinal Application.- Chapter 19. Screening Technique for Heat Shock Protein 90 Inhibitors from Natural Products.- Chapter 20. Therapeutic Effects and Related Molecular Mechanisms of Celastrol, a Triterpenoid Natural Compound and Novel HSP90 Inhibitor Extracted from Plants of the Celastraceae Family.- 

Prof. Dr. Alexzander A. A. Asea is a highly innovative and accomplished world renowned clinical and basic research scientist and visionary executive leader who has exceptional experience spearheading clinical and basic science research, training, education, and commercialization initiatives within top ranked academic biomedical institutes. Prof. Dr. Asea's initial findings studying the effects of Hsp72 on human monocytes lead to the proposal of a novel paradigm that Hsp72, previously known to be an intracellular molecular chaperones, can be found in the extracellular milieu where it has regulatory effects on immuno-competent cells - a term now called chaperokine. Prof. Asea has authored over 255 scientific publications including peer-reviewed articles, reviews, books, book chapters, editorials, and news headliners in a wide range of biomedical-related disciplines. Prof. Asea is the series editor of the widely successful book series Heat Shock Proteins (Springer Nature Publishing) and is an editorial board member of numerous scientific peer-reviewed journals. Currently, Prof. Dr. Asea is at the University of Toledo College of Medicine and Life Sciences in Toledo, USA.

Dr. Punit Kaur is an expert in onco-proteogenomics, with extensive training and experience in quantitative mass spectrometry imaging, protein chemistry and biomarker discovery. Dr. Kaur's main research focus is on the use of heat-induced nanotechnology in combination with radiotherapy and chemotherapy in the cancer stem cell therapy. Dr. Kaur has published more than 40 scientific articles, book chapters, and reviews, and currently serves as editorial board member for the European Journal of Cancer Prevention and the Journal of Proteomics and Bioinformatics. Dr. Kaur is an editor of 10 books in the highly successful Heat Shock Proteins book series by Springer Nature Publishers. Currently, Dr. Kaur is a Visiting Scientist Professor at the University of Texas MD Anderson Cancer